Cellbxhealth PLC (ANPCF)

Cellbxhealth PLC (ANPCF) Healthcare & Pipeline Overview

CelLBxHealth plc, founded in 1994 and based in Guildford, UK, specializes in cancer diagnostics. It develops Parsortix systems for capturing circulating tumor cells (CTCs) from patient blood, alongside complementary staining kits and laboratory services. The company focuses on advancing liquid biopsy solutions for cancer analysis across global markets.

What Is the Investment Thesis for ANPCF?

CelLBxHealth plc is positioned within the rapidly evolving liquid biopsy market, focusing on its proprietary Parsortix systems for circulating tumor cell (CTC) capture. The company's technology addresses a critical need for non-invasive cancer diagnostics, offering intact CTCs for downstream analysis, which can provide valuable insights into cancer progression and treatment response. Key value drivers include the continued adoption of its Parsortix PC1 and PR1 systems in clinical and research settings, particularly for metastatic breast cancer. Strategic partnerships, such as those with BioView for HER2 assays and NuProbe for NGS panels, are expected to broaden its diagnostic utility and market reach, potentially driving revenue growth. The company's gross margin of 31.4% indicates a foundational profitability on its products, although its current negative ROE of -87.2% and negative free cash flow suggest it is in a growth and investment phase. With a debt-to-equity ratio of 31.35, the company maintains a manageable leverage profile. Future catalysts include regulatory approvals for new assays, expanded clinical utility data, and successful commercialization efforts in key geographic markets, which could improve its financial performance and market capitalization from its current $0.00B.

Based on FMP financials and quantitative analysis

ANPCF Key Highlights

• Gross Margin of 31.4% indicates a solid profit margin on its diagnostic products and services.
• Return on Equity (ROE) of -87.2% reflects the company's current investment phase and net losses relative to shareholder equity.
• Debt-to-Equity ratio of 31.35 suggests a moderate level of financial leverage.
• Free Cash Flow (FCF) of $-0.00B indicates the company is currently consuming cash for operations and investments.
• Beta of 0.19 suggests relatively low volatility compared to the broader market, indicating less sensitivity to market fluctuations.

Who Are ANPCF's Competitors?

ANPCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ANPCF's Key Strengths?

• Proprietary Parsortix system for intact CTC capture offers a unique advantage in liquid biopsy.
• Comprehensive product portfolio including devices, kits, and specialized laboratory services.
• Strategic partnerships with BioView and NuProbe expand diagnostic capabilities (HER2, NGS).
• Global presence across the UK, Europe, North America, and other international markets.

What Are ANPCF's Weaknesses?

• Negative Return on Equity (-87.2%) and Free Cash Flow ($-0.00B) indicate unprofitability and cash burn.
• Market capitalization of $6.53M suggests a very small or illiquid market presence.
• Reliance on a niche technology (CTC capture) within the broader liquid biopsy market.
• Disclosure status on OTC market is 'Unknown', potentially limiting investor confidence.

What Could Drive ANPCF Stock Higher?

• Successful clinical validation and regulatory approvals for new diagnostic assays, such as the HER2 assay developed with BioView Ltd, could significantly expand market access and revenue streams.
• Increased adoption rates of the Parsortix PC1 and PR1 systems in new research institutions or clinical laboratories, driven by published efficacy data or expanded commercial efforts.
• Progress in integrating the pan-cancer next generation sequencing (NGS) panel through the partnership with NuProbe USA, Inc., potentially leading to a broader and more comprehensive liquid biopsy offering.
• Expansion of the company's laboratory services, including CTC enrichment and liquid biopsy analysis, attracting new clients and increasing service-based revenue.
• Publication of significant research findings or clinical trial results demonstrating the superior performance or utility of CelLBxHealth's CTC capture technology.

What Are the Key Risks for ANPCF?

• Financial-distress signal — its Altman Z-Score of -21.76 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-87.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition in the liquid biopsy market from companies offering alternative technologies like ctDNA analysis, potentially limiting market share growth.
• The company's current negative Return on Equity (-87.2%) and negative Free Cash Flow ($-0.00B) indicate ongoing unprofitability and a reliance on external funding for operations and growth.
• Regulatory hurdles and lengthy approval processes in key markets could delay the commercialization of new products and assays, impacting revenue timelines.
• As an OTC Other listed stock with 'Unknown' disclosure status, there is a risk of limited liquidity, price volatility, and difficulty for investors to access comprehensive financial information.
• Dependence on the successful execution of strategic partnerships, such as those with BioView and NuProbe, for the development and commercialization of new diagnostic offerings.

What Are the Growth Opportunities for ANPCF?

• **Expanding Adoption of Parsortix Systems**: The Parsortix PC1 and PR1 systems offer a unique advantage in capturing intact circulating tumor cells, crucial for comprehensive downstream analysis in metastatic breast cancer and other solid tumors. As the medical community increasingly recognizes the value of liquid biopsies for non-invasive monitoring and personalized treatment guidance, the demand for robust CTC capture platforms is expected to grow. The global liquid biopsy market, which includes CTC analysis, is projected to reach over $20 billion by 2030. CelLBxHealth can capitalize on this by expanding its commercial footprint and demonstrating further clinical utility, driving adoption in both research and clinical settings globally, particularly in North America and Europe.
• **Growth in Specialized Laboratory Services**: CelLBxHealth offers specialized laboratory services, including CTC enrichment and liquid biopsy analysis. This represents a significant growth opportunity as healthcare providers and pharmaceutical companies increasingly seek outsourced expertise for complex diagnostic procedures. By providing these services, the company can generate recurring revenue streams and establish itself as a key partner in cancer research and clinical trials. The market for contract research organizations (CROs) and specialized lab services is expanding, driven by the complexity of modern diagnostics and the need for specialized equipment and expertise, offering a stable growth path for CelLBxHealth.
• **Leveraging Strategic Partnerships for Expanded Offerings**: The strategic partnerships with BioView Ltd for a human epidermal growth factor receptor 2 (HER2) assay kit and NuProbe USA, Inc. for a pan-cancer next generation sequencing (NGS) panel are pivotal. These collaborations enable CelLBxHealth to broaden its diagnostic portfolio beyond basic CTC capture, integrating more advanced and clinically relevant analyses directly with its Parsortix platform. This expansion into HER2 testing and comprehensive genomic profiling through NGS taps into high-value segments of the oncology diagnostics market, enhancing the utility and market appeal of its overall solution. These partnerships can accelerate product development and market penetration.
• **Development and Commercialization of New Diagnostic Assays**: CelLBxHealth's pipeline includes advanced assays like Portrait Flex for epithelial-to-mesenchymal transition (EMT), DNA damage response, and Portrait PD-L1 for evaluating CTCs. The continuous development and successful commercialization of these specialized assays will be critical growth drivers. These assays provide deeper insights into tumor biology, aiding in prognosis, treatment selection, and monitoring, aligning with the trend towards precision medicine. The market for companion diagnostics and advanced cancer biomarkers is growing rapidly, with significant demand for tools that can guide targeted therapies, offering substantial revenue potential for new, validated assays.
• **Geographic Market Penetration and Expansion**: Currently operating in the United Kingdom, Europe, North America, and internationally, CelLBxHealth has a foundation for global reach. Deepening penetration in existing markets and strategically expanding into new, high-growth regions, particularly in Asia-Pacific and other emerging markets with increasing healthcare spending and cancer incidence, presents a substantial opportunity. Establishing strong distribution networks and securing regulatory approvals in these new territories will be crucial. The global oncology diagnostics market is expanding across all regions, providing ample room for companies with innovative solutions to capture new market share and diversify revenue streams over the next 5-10 years.

What Opportunities Does ANPCF Have?

• Growing global demand for non-invasive cancer diagnostics and personalized medicine.
• Expansion of Parsortix system adoption in new clinical applications and research areas.
• Leveraging partnerships to develop and commercialize new, high-value diagnostic assays.
• Penetration into new geographic markets, particularly emerging economies with rising cancer incidence.

What Threats Does ANPCF Face?

• Intense competition from established diagnostic companies and emerging biotech firms in the liquid biopsy space.
• Rapid technological advancements in ctDNA analysis or other liquid biopsy methods could diminish CTC's competitive edge.
• Regulatory hurdles and lengthy approval processes for new medical devices and diagnostic assays.
• Potential for limited liquidity and investor interest due to OTC market listing and unknown disclosure status.
• Dependence on successful clinical validation and market acceptance of its diagnostic platforms.

What Are ANPCF's Competitive Advantages?

• Proprietary Parsortix technology for capturing intact, viable circulating tumor cells (CTCs), which allows for more comprehensive downstream analysis than fragmented DNA.
• Established intellectual property around its microfluidic cell separation and analysis platforms.
• Strategic partnerships with BioView and NuProbe, integrating advanced assays (HER2, NGS) that enhance the utility and breadth of its liquid biopsy solutions.
• Comprehensive product ecosystem including devices, kits, and laboratory services, creating a 'sticky' customer base.
• Specialized expertise in CTC analysis, a complex and rapidly evolving field, providing a knowledge barrier to entry.

What Does ANPCF Do?

CelLBxHealth plc, originally founded as ANGLE plc in 1994 and subsequently rebranded in October 2025, is a medical diagnostic company headquartered in Guildford, United Kingdom. The company is dedicated to developing advanced cancer diagnostics products, serving markets across the United Kingdom, Europe, North America, and internationally. Its core offerings revolve around the Parsortix system, a proprietary medical device designed for the efficient capture and harvest of intact circulating tumor cells (CTCs) from patient blood. Specifically, the Parsortix PC1 system is tailored for use with metastatic breast cancer patient blood, enabling subsequent user-validated downstream analysis, while the Parsortix PR1 system offers broader CTC capture capabilities. Beyond its flagship systems, CelLBxHealth provides a comprehensive suite of complementary products and services. This includes the Portrait+ CTC Staining kit, a ready-to-use laboratory solution offering high analytical sensitivity and specificity for the identification, characterization, and enumeration of both epithelial and mesenchymal circulating tumor cells. The CellKeep Slide further enhances CTC harvesting technology. The company also extends its expertise through specialized laboratory services, encompassing CTC enrichment and liquid biopsy analysis. Its diagnostic portfolio is further bolstered by assays such as Portrait Flex, an immunofluorescence assay for identifying epithelial, mesenchymal, and epithelial-to-mesenchymal transition markers; DNA damage response assays; and Portrait PD-L1, which evaluates CTCs for PD-L1 expression. Additionally, CelLBxHealth develops custom CTC assays to meet specific research and clinical needs. The company strategically expands its capabilities through partnerships, including an agreement with BioView Ltd to develop a human epidermal growth factor receptor 2 (HER2) assay kit for breast cancer, and a collaboration with NuProbe USA, Inc. to integrate a pan-cancer next generation sequencing (NGS) panel into its offerings, underscoring its commitment to innovation in liquid biopsy.

What Products and Services Does ANPCF Offer?

• Develops and commercializes Parsortix PC1 and PR1 systems for capturing intact circulating tumor cells (CTCs) from patient blood.
• Provides the Portrait+ CTC Staining kit for identifying, characterizing, and enumerating epithelial and mesenchymal CTCs.
• Offers the CellKeep Slide, a technology designed for efficient CTC harvesting.
• Delivers specialized laboratory services, including CTC enrichment and comprehensive liquid biopsy analysis.
• Develops and markets immunofluorescence assays like Portrait Flex for EMT and DNA damage response, and Portrait PD-L1 for CTC evaluation.
• Creates custom CTC assays tailored to specific research and clinical requirements.
• Engages in strategic partnerships to develop new diagnostic capabilities, such as a HER2 assay with BioView Ltd.
• Collaborates to integrate advanced genomic profiling, like a pan-cancer next generation sequencing (NGS) panel with NuProbe USA, Inc.

How Does ANPCF Make Money?

• Sells Parsortix medical devices (PC1 and PR1 systems) to research institutions, hospitals, and diagnostic laboratories.
• Generates revenue from the sale of consumable kits, such as the Portrait+ CTC Staining kit and CellKeep Slides, essential for system operation.
• Provides specialized laboratory services, offering CTC enrichment and liquid biopsy analysis on a fee-for-service basis.
• Licenses or partners for the development and commercialization of new diagnostic assays, potentially involving royalty agreements or milestone payments.
• Develops and sells proprietary diagnostic assays (e.g., Portrait Flex, Portrait PD-L1) for advanced cancer characterization.

What Industry Does ANPCF Operate In?

CelLBxHealth plc operates within the dynamic and high-growth Medical - Diagnostics & Research industry, specifically targeting the liquid biopsy segment of cancer diagnostics. This market is characterized by increasing demand for non-invasive, early detection, and personalized medicine solutions. The global liquid biopsy market size was valued at approximately $4.5 billion in 2023 and is projected to grow significantly, driven by technological advancements and rising cancer prevalence. CelLBxHealth's focus on circulating tumor cell (CTC) capture positions it within a specialized niche, differentiating it from companies primarily focused on circulating tumor DNA (ctDNA). The competitive landscape includes established diagnostic giants and numerous biotech startups, all vying for market share with various liquid biopsy approaches. CelLBxHealth's Parsortix system, which aims to provide intact CTCs for comprehensive downstream analysis, offers a unique value proposition in this competitive environment, seeking to address limitations of other liquid biopsy methods by enabling a broader range of analyses.

Who Are ANPCF's Key Customers?

• Oncology research institutions and academic medical centers seeking advanced CTC analysis tools.
• Clinical laboratories and hospitals implementing liquid biopsy for cancer diagnosis, monitoring, and treatment selection.
• Pharmaceutical and biotechnology companies utilizing CTC analysis in drug development and clinical trials.
• Contract Research Organizations (CROs) requiring specialized diagnostic services for their clients.
• Pathology departments and specialized diagnostic centers focused on precision oncology.

Company Profile

Cellbxhealth PLC operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Guildford, GB. The company is led by CEO Peter Michael Collins. ANPCF has traded publicly since 2014.

Cellbxhealth PLC Financial Trajectory

Cellbxhealth PLC (ANPCF) reported $555K in revenue for Q4 2025, reflecting 39.4% growth compared to the prior quarter. The company recorded a net loss of $10.2M, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, ANPCF averaged $-0.01 in diluted EPS.

How Cellbxhealth PLC Is Valued

Cellbxhealth PLC carries a market capitalization of $6.53M, placing it in the micro-cap category. Relative to its peer group, ANPCF's quantitative score of 59/100 is roughly in line with the peer average of 66/100.

ROE -87%Key Financial Metrics

Return on equity for Cellbxhealth PLC stands at -87.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.0%, showing how much profit it generates from its asset base. ANPCF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.13 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Cellbxhealth PLC's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -21.76 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Cellbxhealth PLC revenue of about $2.1M for fiscal 2026, with EPS near $-0.00.

ANPCF Financials

ANPCF Latest News

ANPCF Analyst Consensus

ANPCF MoonshotScore

Common Questions About ANPCF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources